Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010

Simon Harrison, Phoebe Joy Ho, Sueh-Li Lim, Stephanie Talam, Hannah Pahl, Dharmesh Dingar, Scott Currence, Travis Quigley, Andrew Spencer

Blood (2025) 146 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2025-LBA-1

Published: 2025

Journal Articles

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

Jian Li, Mark Dowling, Anthony Jeffrey, Sergio Farina, Stephen Boyle, Ross MacDonald, Shafqat Inam, Chun Kei Kris Ma, Vinay Vanguru, Nilu Perera, Hamish Scott, Michael Dickinson, John Seymour, Andrea Henden, Emily Blyth, Phoebe Joy Ho, Constantine Tam, Mary Ann Anderson, Philip Thompson

Blood (2025) 146 (Supplement 1): 2779.

https://doi.org/10.1182/blood-2025-2779

Published: 2025

Journal Articles

A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium

Blood (2025) 146 (Supplement 1): 399.

https://doi.org/10.1182/blood-2025-399

Published: 2025

Journal Articles

Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups.

Ghassan Zammar, Bradley Augustson, Elizabeth Moore, M Hasib Sidiqi, Cameron Wellard, Elham Ashrafi, Simon Harrison, Dejan Radeski, Alannah Jackson, Krystal Bergin, Phoebe Joy Ho, Tracy King, Peter Mollee, Hang Quach, Rajeev Rajagopal, Zoe McQuilten, Erica Wood, Brian Rosengarten, Andrew Spencer

Blood (2025) 146 (Supplement 1): 2221.

https://doi.org/10.1182/blood-2025-2221

Published: 2025

Journal Articles

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Blood (2025) 146 (Supplement 1): 5820.

https://doi.org/10.1182/blood-2025-5820

Published: 2025

Journal Articles

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 94.

https://doi.org/10.1182/blood-2025-94

Published: 2025

Journal Articles

Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2262.

https://doi.org/10.1182/blood-2025-2262

Published: 2025

Journal Articles

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

Blood (2025) 146 (Supplement 1): 2265.

https://doi.org/10.1182/blood-2025-2265

Published: 2025

Journal Articles

Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in Relapsed/Refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study

Phoebe Joy Ho, Hang Quach, Sosana Delimpasi, Armando Santoro, Cindy H-S Lee, Nicolas Kint, Sylvia Faict, Yanke Yu, Olivier Catalani, Ameet Mishra, Tulika Tyagi, Clare Devlin, Semira Sheikh, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 700.

https://doi.org/10.1182/blood-2025-700

Published: 2025

Journal Articles

Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Blood (2025) 146 (Supplement 1): 2302.

https://doi.org/10.1182/blood-2025-2302

Published: 2025

Journal Articles

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Blood (2025) 146 (Supplement 1): 468.

https://doi.org/10.1182/blood-2025-468

Published: 2025

Journal Articles

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Binod Dhakal, Hang Quach, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Peter Tan, Tara Cochrane, Hanlon Sia, Jeffrey A. Zonder, Camille Martinet, Dominique Duchesne, Andrew Garton, Vinu Menon, Beata Holkova, Cyril Konto, Lida Pacaud, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2024-209952

Published: 2024

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Blood (2024) 144 (Supplement 1): 772.

https://doi.org/10.1182/blood-2024-200336

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Blood (2023) 142 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2023-191911

Published: 2023

Journal Articles

Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries

Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, Slavisa Ninkovic, Wee-Joo Chng, Andrew Spencer, Peter Mollee, Jay Hocking, Phoebe Joy Ho, Wojt Janowski, Kihyun Kim, Karen Dun, Zoe K McQuilten, Fiona Chen, Hang Quach

Blood (2023) 142 (Supplement 1): 3325.

https://doi.org/10.1182/blood-2023-173896

Published: 2023

Journal Articles

A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma

Andy Tang, Kihyun Kim, Fiona Chen, Zoe K McQuilten, Peter Mollee, Rajeev Rajagopal, Hang Quach, Phoebe Joy Ho, Simon J. Harrison, Andrew Spencer, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2023-178192

Published: 2023

Journal Articles

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 4707.

https://doi.org/10.1182/blood-2023-186241

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium

Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups.

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in Relapsed/Refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study

Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries

A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only